Vivo Capital Overview and Investment Strategy

Vivo Capital is a healthcare-focused private equity firm that has been investing in the industry for over two decades. Vivo Capital was founded in 1996, and since then, it has established itself as a leading player in the healthcare investment space.

Vivo Capital has a unique investment strategy that focuses on investing in innovative healthcare companies that have the potential to make a significant impact. The firm's investment strategy is centered around identifying and investing in companies that have a strong track record of innovation and growth.

Vivo Capital's team of experienced investment professionals has a deep understanding of the healthcare industry and is able to identify opportunities that others may miss.

Vivo Capital is a fund manager with a significant presence in the industry. They have 21 funds under their management.

One notable fund managed by Vivo Capital is the Vivo (Suzhou) Health Industry Investment Fund, which closed on December 21, 2023, with an amount of $1,400M.

Vivo Capital Fund IX is another notable fund, which closed on October 30, 2019, with a multi-stage venture capital approach and a total amount of $1,430M.

Here are some of the funds managed by Vivo Capital, along with their closing dates and amounts:

Vivo Capital is a global healthcare investment firm that focuses on supporting innovative companies in the biopharmaceutical and medical technology sectors.

Established in 2000 by Dr. Fuad El-Hibri and Dr. Rainer Strohmenger, Vivo Capital has a strong presence in the US, China, and Europe.

With a team of experienced investment professionals, Vivo Capital has invested in over 200 companies worldwide, providing strategic guidance and resources to help them grow and succeed.

Vivo Capital's investment approach is centered around partnering with talented entrepreneurs and management teams to build and grow their businesses.

The firm's investment portfolio includes companies that are focused on developing innovative treatments for various diseases and conditions, as well as those that are improving healthcare delivery and outcomes.

Vivo Capital's commitment to supporting innovative healthcare companies has enabled them to make a significant impact in the industry.

Vivo Capital has a total of 21 funds, including the Vivo (Suzhou) Health Industry Investment Fund.

One of Vivo Capital's notable funds is the Vivo Capital Fund IX, which was closed on October 30, 2019, and had an amount of $1,430M.

The Vivo Capital Fund X was launched on January 3, 2023, with a relatively smaller amount of $60M.

Here's a breakdown of some of Vivo Capital's notable funds:

Vivo Capital has made a significant number of investments, with a total of 343 investments to their name. Their latest investment was in TrendTec as part of their Private Equity on December 01, 2024.

They have also been actively involved in acquisitions, having acquired 6 companies. Their latest acquisition was Seran BioScience on September 17, 2024, with a valuation of $XXM.

Here are some key facts about Vivo Capital's investments and acquisitions:

Vivo Capital has a significant presence in the investment world with 21 funds under its umbrella.

One notable investment is the Vivo (Suzhou) Health Industry Investment Fund, which closed in December 2023 with a massive $1.4 billion in funding.

The Vivo Capital Fund X, on the other hand, was launched in January 2023 with a relatively modest $60 million in funding.

Another example is the Vivo Capital Fund IX, which closed in October 2019 with a staggering $1.43 billion in funding, making it a substantial investment in the venture capital space.

The Vivo Opportunity Co-Invest (W) and Vivo Opportunity Co-Invest funds also have unknown amounts of funding, but they were launched in May and April 2019 respectively.

Here's a breakdown of Vivo Capital's notable investments:

Vivo Capital has an impressive 102 portfolio exits. Their latest exit was Zenas BioPharma, which went public on September 13, 2024.

One of the notable exits was RayzeBio, another biotech company that went public on September 15, 2023.

Vivo Capital's portfolio exits are not limited to IPOs. They have also had successful acquisitions, such as the purchase of Satsuma Pharmaceuticals by Shin Nippon Biomedical Laboratories on June 8, 2023.

The valuation of these exits is not publicly disclosed, but it's clear that Vivo Capital has a track record of successful investments.

Here are the details of Vivo Capital's portfolio exits:

These exits demonstrate Vivo Capital's ability to identify and support successful companies in various industries.

Vivo Capital has a strong network of partners and customers, with a notable partnership with Ascendis Pharma.

Vivo Capital partnered with Ascendis Pharma on November 8, 2018, to form VISEN Pharmaceuticals.

This partnership was announced to develop and commercialize TransCon Endocrinology Rare Disease Therapies in China.

Vivo Capital is a global investment firm that focuses on life sciences and healthcare investments. It was founded in 2001 by a team of experienced investors and entrepreneurs.

The firm has a strong presence in the life sciences and healthcare industry, with a focus on investing in companies that have the potential to transform patient outcomes. Vivo Capital has a deep understanding of the industry and its trends, which enables it to make informed investment decisions.

Vivo Capital has a diverse portfolio of investments, including companies that are working on innovative treatments for diseases, as well as those that are developing new medical technologies. Its investments have resulted in significant returns for its investors.

The firm has a team of experienced investment professionals who have a strong track record of success in the life sciences and healthcare industry. They have a deep understanding of the industry and its trends, which enables them to make informed investment decisions.

Vivo Capital is headquartered in San Francisco, California, and has additional offices in New York and Hong Kong.

35Pharma, a clinical-stage biopharmaceutical company, recently closed an oversubscribed $53 million Series C financing.

The financing was led by Frazier Life Sciences with participation from new investors including Vivo Capital, Janus Henderson Investors, Deep Track Capital, Paradigm BioCapital Advisors, and Columbia Threadneedle.

Vivo Capital was one of the new investors to participate in the Series C financing, which will support initial clinical proof-of-concept studies for HS135 in pulmonary hypertension, as well as advance HS235 through a Phase 1 proof-of-biology trial in obese and overweight healthy volunteers.

35Pharma plans to use the proceeds to advance its pipeline of Activin and GDF inhibitors, including HS135 for pulmonary hypertension and HS235 for cardiometabolic disease and obesity.

The company is focused on developing best-in-class transforming growth factor-beta (TGF-beta) superfamily ligand traps for pulmonary hypertension, obesity, and cardiometabolic diseases.